Skip to main content
SpringerLink
Log in

Trifarotene: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chien AL. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12 Suppl):s51–5.

    PubMed  Google Scholar 

  2. Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345–65.

    Article  Google Scholar 

  3. US National Institue of Health. Lamellar ichthyosis. 2019. http://ghr.nlm.nih.gov/condition/lamellar-ichthyosis#diagnosis. Accessed 15 Oct 2019.

  4. Vahlquist A, Fischer J, Törmä H. Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):51–66.

    Article  Google Scholar 

  5. FDA. Novel drug approvals for 2019. 2019. http://www.fda.gov. Accessed 15 Oct 2019.

  6. Galderma. Aklief® (Trifarotene): US Prescribing Information. 2019. http://www.galderma.com/. Accessed 2019 Oct 8.

  7. Galderma. Galderma trifarotene development program meets key milestone for lamellar ichthyosis orphan disease [media release]. 2016. http://www.galderma.com/. Accessed 15 Oct 2019.

  8. Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179(2):442–56.

    CAS  PubMed  Google Scholar 

  9. Thoreau E, Arlabosse J, Bouix-Peter C, et al. Structure-based design of trifarotene, a potent and selective RAR agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;128(101736-41).

  10. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.

    Article  CAS  Google Scholar 

  11. Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2019. https://doi.org/10.1111/jdv.15794.

    Article  PubMed  Google Scholar 

  12. Galderma (2019) Data on file

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Lesley J. Scott

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material

For this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshre.9978725.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Trifarotene: First Approval. Drugs 79, 1905–1909 (2019). https://doi.org/10.1007/s40265-019-01218-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01218-6

Search

Navigation